---
title: "RHM: Record Q2 growth and a strong order backlog underpin confidence in 2026 guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295059479.md"
description: "Record Q2 sales and operating results, with strong growth across all segments and a robust order backlog, support high confidence in meeting updated 2026 guidance. Inventory build-up and capex optimization position the company for continued expansion amid rising European defense spending.Original document: Rheinmetall AG [RHM] Slides Release — Aug. 6 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-06T05:35:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295059479.md)
  - [en](https://longbridge.com/en/news/295059479.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295059479.md)
generator: "portal-rs"
---

# RHM: Record Q2 growth and a strong order backlog underpin confidence in 2026 guidance

Record Q2 sales and operating results, with strong growth across all segments and a robust order backlog, support high confidence in meeting updated 2026 guidance. Inventory build-up and capex optimization position the company for continued expansion amid rising European defense spending.

Original document: Rheinmetall AG \[RHM\] Slides Release — Aug. 6 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [RHM.DE](https://longbridge.com/en/quote/RHM.DE.md)
- [RNMBY.US](https://longbridge.com/en/quote/RNMBY.US.md)

## Related News & Research

- [RHM: Strong sales and profit growth driven by defense demand, major orders, and NVL acquisition](https://longbridge.com/en/news/295059634.md)
- [Consulting's race to become AI native](https://longbridge.com/en/news/296676838.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [PFSE: Record Q2 revenue and profit growth, driven by strong demand and innovation in HVDC technology](https://longbridge.com/en/news/296308264.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**